Physician profile
Thomas Swantkowski
NPI 1144265109
$13,557.11
in general payments reported to CMS, 2019-2025
38 companies · $3,323 in 2025
The $3,323 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,655 · 2020: $71.62 · 2021: $311 · 2022: $639 · 2023: $1,427 · 2024: $2,131 · 2025: $3,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,861 · Travel and Lodging: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,861.02 |
| Travel and Lodging | $1,019.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,634.67 | 2019 | |
| Abbvie INC. | $3,053.89 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Enterra Medical, INC. | $1,583.70 | 2024-2025 | |
| Janssen Biotech, INC. | $466.06 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $422.61 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $343.30 | 2019-2025 | Livdelzi |
| Pfizer INC. | $297.36 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $282.70 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $221.30 | 2022-2023 | Zeposia |
| Qol Medical, LLC | $189.32 | 2024-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $183.81 | 2023-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.88 | 2019-2025 | Xifaxan, Trulance |
| Boston Scientific Corporation | $156.69 | 2019-2024 | Watchman Flx |
| Pharmacosmos Therapeutics INC. | $150.00 | 2025 | Monoferric |
| Janssen Scientific Affairs, LLC | $147.39 | 2024 | Tremfya |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Swantkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.